Vaccine Development Summary
#61
Merck starting trails on two candidates later this year.
https://www.reuters.com/article/us-m...-idUSKCN24W1MR
https://www.reuters.com/article/us-m...-idUSKCN24W1MR
#62
#63
:-)
Joined APC: Feb 2007
Posts: 7,339
#64
Thats where therapeutics come to play. Just like the flu vaccine, some will still get sick. But if you go to the doctor and can be given medicine to reduce the duration and severity of the symptoms, then life goes on. Antivirals, monoclonal antibodies, etc. The vaccine is only one piece of the puzzle.
#65
Banned
Joined APC: Oct 2010
Posts: 1,222
Thats where therapeutics come to play. Just like the flu vaccine, some will still get sick. But if you go to the doctor and can be given medicine to reduce the duration and severity of the symptoms, then life goes on. Antivirals, monoclonal antibodies, etc. The vaccine is only one piece of the puzzle.
Nope, you get the Vid you might as well pick out your tombstone...that 99.5% survival rate is just a number
Literally everyone who catches the Vid is a goner! It's science
#66
Thats where therapeutics come to play. Just like the flu vaccine, some will still get sick. But if you go to the doctor and can be given medicine to reduce the duration and severity of the symptoms, then life goes on. Antivirals, monoclonal antibodies, etc. The vaccine is only one piece of the puzzle.
#67
Brief history of enhanced RSV disease.In 1966, a formalin-inactivated vaccine against RSV (FIRSV) was administered to infants and children in four studies in the United States (26–29). The immunized children were exposed to RSV in the community, and those children who were seronegative for the virus before vaccination experienced a significant increase in the frequency and severity of RSV LRTI. This enhanced form of RSV disease presented with fever, wheezing, and bronchopneumonia and led to frequent hospitalizations (80% in FIRSV recipients versus 5% in controls among RSV-infected children in one study) (26). In fact, two immunized infants died as toddlers as a consequence of subsequent RSV infection (26).
#68
New dengue vaccine performs well in large trial, but safety remains key concern
By Jon CohenNov. 6, 2019 , 5:00 PMAn experimental dengue vaccine has shown promising early results in a large, multicountry trial, but critical questions remain about its effectiveness and safety. Still unclear, for example, is whether the vaccine—which had an efficacy of 80.2% in the study—might increase disease severity in some recipients, as happened with a dengue vaccine given to 1 million children in the Philippines before the problem became clear in 2017.
Critics ‘alarmed by lack of interest’ in studying children put at risk by dengue vaccine
By Jon CohenSep. 4, 2019 , 11:30 AMPublic health experts are debating how to help the 1 million children in the Philippines who received a new vaccine against dengue that could, in rare cases, sicken rather than protect them. The country launched a campaign in 2016 to vaccinate schoolchildren against the mosquito-borne virus, which can cause high fevers, muscle and joint pains, and rashes. One year later, the campaign was suddenly halted after the vaccine’s producer, Paris-based Sanofi Pasteur, announced it could, in rare cases, trigger severe, potentially fatal forms of dengue in children who became infected with the virus despite their vaccination.
Now, critics of the vaccine, named Dengvaxia, say researchers should try to identify those at increased risk of harm, which might save their lives. But Sanofi Pasteur has no plans to conduct a big, complex study, although it is following the fate of about 1% of the vaccinated children for 5 years. “I’m pretty alarmed by the lack of interest,” says retired dengue researcher Scott Halstead, who worked at the Uniformed Services University of the Health Sciences in Bethesda, Maryland, for many years.
Although an epidemic now underway in the Philippines that has sickened nearly 170,000 people likely will have little impact on the frequency of this rare event, it has brought the issue into sharper focus. Halstead calculates that some 500 Filipino children annually could develop severe dengue because of their earlier vaccination with Dengvaxia
#69
Gets Weekends Off
Joined APC: May 2020
Posts: 484
So let me ask since you throw out some small risk to every vaccine statement. What is your plan B cargo? Realizing that your plan has to control infections or the rest of the world is not letting us in. What’s the plan?
#70
THAT was the point that was being made in the articles I referenced. I am, as I said , not in the least opposed to vaccine development and believe that all too many people fail to avail themselves of immunizations they ought to get.
I am concerned, however, that the expectations of most people touting the COVID vaccine as the answer to the pandemic indicate they do not understand how quickly a safe and effective vaccine can be produced. And their expectations of how effective that vaccine might be, and how soon a mass immunization program based upon it could help the current situation are UNREALISTIC.
There is also the ethical issue of immunizing those healthy young people to whom COVID-19 represents a fairly trivial risk to provide herd immunity to benefit the elderly and those with multiple comorbidiies and how willing those young healthy people are going to be to be vaccinated with a vaccine with little track record for - mainly - the benefit of others.
Those are real issues however much you might want to pretend they are not.
Last edited by Excargodog; 07-31-2020 at 05:10 PM.
Thread
Thread Starter
Forum
Replies
Last Post